SI1740569T1 - Imidazolni derivati kot inhibitorji TAFIa - Google Patents
Imidazolni derivati kot inhibitorji TAFIaInfo
- Publication number
- SI1740569T1 SI1740569T1 SI200530185T SI200530185T SI1740569T1 SI 1740569 T1 SI1740569 T1 SI 1740569T1 SI 200530185 T SI200530185 T SI 200530185T SI 200530185 T SI200530185 T SI 200530185T SI 1740569 T1 SI1740569 T1 SI 1740569T1
- Authority
- SI
- Slovenia
- Prior art keywords
- imidazole derivatives
- derivatives used
- tafia inhibitors
- tafia
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004020186A DE102004020186A1 (de) | 2004-04-22 | 2004-04-22 | Heterocyclylessigsäuren als Inhibitoren von TAFla |
EP05731221A EP1740569B1 (de) | 2004-04-22 | 2005-04-07 | Imidazol-derivate als tafia-inhibitoren |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1740569T1 true SI1740569T1 (sl) | 2008-06-30 |
Family
ID=34964308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200530185T SI1740569T1 (sl) | 2004-04-22 | 2005-04-07 | Imidazolni derivati kot inhibitorji TAFIa |
Country Status (35)
Country | Link |
---|---|
EP (2) | EP1864979B1 (sl) |
JP (1) | JP4939401B2 (sl) |
KR (1) | KR101162047B1 (sl) |
CN (1) | CN100572376C (sl) |
AR (1) | AR053302A1 (sl) |
AT (2) | ATE523505T1 (sl) |
AU (1) | AU2005238144B2 (sl) |
BR (1) | BRPI0510159A (sl) |
CA (1) | CA2563401C (sl) |
CR (1) | CR8650A (sl) |
CY (1) | CY1108087T1 (sl) |
DE (2) | DE102004020186A1 (sl) |
DK (1) | DK1740569T3 (sl) |
EC (1) | ECSP066941A (sl) |
ES (1) | ES2299026T3 (sl) |
HK (1) | HK1101823A1 (sl) |
HR (1) | HRP20080099T3 (sl) |
IL (1) | IL178672A (sl) |
MA (1) | MA28543B1 (sl) |
MY (1) | MY140903A (sl) |
NI (1) | NI200600217A (sl) |
NO (1) | NO20065320L (sl) |
NZ (1) | NZ550757A (sl) |
PE (1) | PE20060172A1 (sl) |
PL (1) | PL1740569T3 (sl) |
PT (1) | PT1740569E (sl) |
RS (1) | RS50553B (sl) |
RU (1) | RU2375356C2 (sl) |
SI (1) | SI1740569T1 (sl) |
TN (1) | TNSN06341A1 (sl) |
TW (1) | TWI359016B (sl) |
UA (1) | UA87306C2 (sl) |
UY (1) | UY28868A1 (sl) |
WO (1) | WO2005105781A1 (sl) |
ZA (1) | ZA200607668B (sl) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0720241A2 (pt) | 2006-12-06 | 2013-12-31 | Sanofi Aventis | Derivados de ureia e sulfamida como inibidores de tafia |
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
MX2009008777A (es) * | 2007-02-13 | 2009-08-25 | Schering Corp | Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos. |
JP5489997B2 (ja) | 2007-07-19 | 2014-05-14 | シマベイ セラピューティクス, インコーポレーテッド | 糖尿病および代謝疾患の治療のためのRUP3またはGPRl19受容体のアゴニストとしてのN−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体 |
WO2009103432A2 (en) * | 2008-02-21 | 2009-08-27 | Sanofi-Aventis | Covalently binding imaging probes |
US8580777B2 (en) | 2008-06-06 | 2013-11-12 | Sanofi | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa |
JPWO2010050525A1 (ja) | 2008-10-29 | 2012-03-29 | 大正製薬株式会社 | TAFIa阻害活性を有する化合物 |
EP2430002B1 (en) * | 2009-05-15 | 2013-07-24 | Sanofi | Process for the preparation of a compound useful as an inhibitor of tafia |
FR2947266B1 (fr) * | 2009-06-26 | 2011-06-17 | Servier Lab | Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
ES2497566T3 (es) | 2009-10-01 | 2014-09-23 | Cymabay Therapeutics, Inc. | Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida |
SG182767A1 (en) * | 2010-03-18 | 2012-08-30 | Daiichi Sankyo Co Ltd | Cycloalkyl-substituted imidazole derivative |
ES2608779T3 (es) | 2010-03-18 | 2017-04-17 | Daiichi Sankyo Company, Limited | Derivado de ácido ciclopropanocarboxílico |
BR112013011244A2 (pt) | 2010-11-11 | 2017-10-24 | Sanofi Sa | processo para a preparação de derivados e ácido 3-(6-amino-piridin-3il)-2-acrílico |
EP2782576B1 (en) * | 2011-11-25 | 2016-05-18 | Sanofi | Sodium salt of (r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid |
WO2013076178A1 (en) | 2011-11-25 | 2013-05-30 | Sanofi | Crystalline salts of r)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1h-imidazol-4-yl)-propionic acid |
EP2782574B1 (de) | 2011-11-25 | 2016-03-30 | Sanofi | Salz von (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl)- propionsäureethylester |
EP3184095A1 (en) | 2013-05-23 | 2017-06-28 | IP Gesellschaft für Management mbH | Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide |
JP6461113B2 (ja) | 2013-06-10 | 2019-01-30 | サノフイSanofi | TAFIaの阻害剤としての大環状尿素誘導体、それらの製造および医薬としての使用 |
CN108883094A (zh) | 2016-03-29 | 2018-11-23 | 第三共株式会社 | 炎症性肠病治疗剂 |
EP3493807A1 (en) | 2016-08-03 | 2019-06-12 | CymaBay Therapeutics, Inc. | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003013526A1 (en) | 2001-08-08 | 2003-02-20 | Merck & Co. Inc. | Anticoagulant compounds |
MXPA04005940A (es) | 2002-01-22 | 2004-09-13 | Pfizer | Acidos 3-(imidazolil)-2-aminopropanoicos. |
-
2004
- 2004-04-22 DE DE102004020186A patent/DE102004020186A1/de not_active Withdrawn
-
2005
- 2005-04-06 PE PE2005000382A patent/PE20060172A1/es not_active Application Discontinuation
- 2005-04-07 SI SI200530185T patent/SI1740569T1/sl unknown
- 2005-04-07 DE DE502005002927T patent/DE502005002927D1/de active Active
- 2005-04-07 ES ES05731221T patent/ES2299026T3/es active Active
- 2005-04-07 AT AT07017340T patent/ATE523505T1/de active
- 2005-04-07 PL PL05731221T patent/PL1740569T3/pl unknown
- 2005-04-07 NZ NZ550757A patent/NZ550757A/en not_active IP Right Cessation
- 2005-04-07 WO PCT/EP2005/003630 patent/WO2005105781A1/de active Application Filing
- 2005-04-07 AT AT05731221T patent/ATE386737T1/de active
- 2005-04-07 RS RSP-2008/0107A patent/RS50553B/sr unknown
- 2005-04-07 CA CA2563401A patent/CA2563401C/en not_active Expired - Fee Related
- 2005-04-07 JP JP2007508756A patent/JP4939401B2/ja not_active Expired - Fee Related
- 2005-04-07 PT PT05731221T patent/PT1740569E/pt unknown
- 2005-04-07 EP EP07017340A patent/EP1864979B1/de active Active
- 2005-04-07 RU RU2006141246/04A patent/RU2375356C2/ru not_active IP Right Cessation
- 2005-04-07 EP EP05731221A patent/EP1740569B1/de active Active
- 2005-04-07 KR KR1020067021881A patent/KR101162047B1/ko not_active IP Right Cessation
- 2005-04-07 CN CNB2005800115593A patent/CN100572376C/zh not_active Expired - Fee Related
- 2005-04-07 BR BRPI0510159-0A patent/BRPI0510159A/pt not_active Application Discontinuation
- 2005-04-07 AU AU2005238144A patent/AU2005238144B2/en not_active Ceased
- 2005-04-07 DK DK05731221T patent/DK1740569T3/da active
- 2005-04-20 TW TW094112493A patent/TWI359016B/zh not_active IP Right Cessation
- 2005-04-20 MY MYPI20051748A patent/MY140903A/en unknown
- 2005-04-20 AR ARP050101556A patent/AR053302A1/es not_active Application Discontinuation
- 2005-04-22 UY UY28868A patent/UY28868A1/es unknown
- 2005-07-04 UA UAA200612254A patent/UA87306C2/ru unknown
-
2006
- 2006-09-13 ZA ZA200607668A patent/ZA200607668B/en unknown
- 2006-09-20 NI NI200600217A patent/NI200600217A/es unknown
- 2006-09-22 CR CR8650A patent/CR8650A/es unknown
- 2006-10-17 IL IL178672A patent/IL178672A/en not_active IP Right Cessation
- 2006-10-19 MA MA29399A patent/MA28543B1/fr unknown
- 2006-10-20 TN TNP2006000341A patent/TNSN06341A1/en unknown
- 2006-10-20 EC EC2006006941A patent/ECSP066941A/es unknown
- 2006-11-20 NO NO20065320A patent/NO20065320L/no not_active Application Discontinuation
-
2007
- 2007-09-03 HK HK07109537.4A patent/HK1101823A1/xx not_active IP Right Cessation
-
2008
- 2008-03-06 HR HR20080099T patent/HRP20080099T3/xx unknown
- 2008-05-12 CY CY20081100491T patent/CY1108087T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL178672A0 (en) | Imidazole derivatives used as tafia inhibitors | |
HK1105592A1 (en) | Aryl-pyridine derivatives as 1-beta-hsd1 inhibitors | |
ZA200702394B (en) | Indozolone derivatives as 11b-HSD1 inhibitors | |
IL194582A0 (en) | Condensed imidazole derivatives as aromatase inhibitors | |
HK1133650A1 (en) | Hydantoin derivatives used as mmp inhibitors | |
IL198247A0 (en) | Indazole derivatives useful as l-cpt1 inhibitors | |
EP1790650B1 (en) | NEW SUBSTITUTED IMIDAZOLE DERIVATIVES | |
HK1135391A1 (en) | Triazole derivatives as kinase inhibitors | |
ZA200610771B (en) | Quinazolinedolone derivatives as PARP inhibitors | |
IL193482A0 (en) | Hydantoin based kinase inhibitors | |
PL1763517T3 (pl) | Pochodne pirymidyny jako inhibitory 11BETA-HSD1 | |
IL183599A0 (en) | Novel hydantoin derivatives as metalloproteinase inhibitors | |
ZA200904175B (en) | Imidazole derivatives as kinesin spindle protein inhibitors (EG-5) | |
ZA200705076B (en) | Novel hydantoin derivatives as metalloproteinase inhibitors | |
HK1108435A1 (en) | Hydantoin derivatives useful as metalloproteinase inhibitors | |
SI1937673T1 (sl) | Imidazolovi derivati kot inhibitorji TAFIa | |
SI2104497T1 (sl) | Derivati sulfamida kot inhibitorji TAFIa | |
ZA200608998B (en) | Imidazole derivatives as tyrosine kinase inhibitors | |
IL184559A0 (en) | Imidazole derivatives | |
ZA200806993B (en) | Hydantoin based kinase inhibitors |